Advanced in Cerebellum Agenesis Hydrocephaly

Dr. Michael Schulder

Neurosurgery
North Shore-Lij Medical PC
300 Community Dr, 
Manhasset, NY 
Advanced in Cerebellum Agenesis Hydrocephaly
North Shore-Lij Medical PC
300 Community Dr, 
Manhasset, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Schulder is a Neurosurgery provider in Manhasset, New York. Dr. Schulder is rated as an Advanced provider by MediFind in the treatment of Cerebellum Agenesis Hydrocephaly. His top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, Gamma Knife Radiosurgery, and Awake Craniotomy.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in NJ
Hospital Affiliations
Long Island Jewish Medical Center
North Shore University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

NORTH SHORE-LIJ MEDICAL PC
300 Community Dr, Manhasset, NY 11030
Other Locations
NORTH SHORE-LIJ MEDICAL PC
330 Community Dr, Manhasset, NY 11030
NORTH SHORE-LIJ MEDICAL PC
350 Community Dr, Manhasset, NY 11030
NORTH SHORE-LIJ MEDICAL PC
450 Lakeville Rd, New Hyde Park, NY 11042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)
Enrollment Status: Withdrawn
Publish Date: March 15, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

93 Total Publications

Optimizing patient positioning for exoscopic cranial surgery.
Optimizing patient positioning for exoscopic cranial surgery.
Journal: Neurosurgical focus: Video
Published: October 20, 2025
Similar Doctors
Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Guy M. Mckhann
Neurosurgery
Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Guy M. Mckhann
Neurosurgery

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (13.2 miles away)
212-305-4931
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Guy Mckhann is a Neurosurgery provider in New York, New York. Dr. Mckhann is rated as a Distinguished provider by MediFind in the treatment of Cerebellum Agenesis Hydrocephaly. His top areas of expertise are Hydrocephalus, Cerebellum Agenesis Hydrocephaly, Congenital Cardiovascular Shunt, Gamma Knife Radiosurgery, and Awake Craniotomy.

Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Stephen M. Bloomfield
Neurosurgery | Neurology
Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Stephen M. Bloomfield
Neurosurgery | Neurology

Hackensack Meridian Health Medical Group - Specialty Care PC

65 James St, 
Edison, NJ 
 (37.3 miles away)
732-321-7189
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Bloomfield is a Neurosurgery specialist and a Neurologist in Edison, New Jersey. Dr. Bloomfield is rated as a Distinguished provider by MediFind in the treatment of Cerebellum Agenesis Hydrocephaly. His top areas of expertise are Cerebellum Agenesis Hydrocephaly, Hydrocephalus, Primitive Neuroectodermal Tumor (PNET), Awake Craniotomy, and Deep Brain Stimulation.

Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Steven Schneider
Neurosurgery
Distinguished in Cerebellum Agenesis Hydrocephaly
Dr. Steven Schneider
Neurosurgery

Long Island Neurosurgical Associates PC

410 Lakeville Rd, Suite 204, 
New Hyde Park, NY 
 (1.4 miles away)
516-354-3401
Experience:
43+ years
Languages Spoken:
English
See accepted insurances

Steven Schneider is a Neurosurgery provider in New Hyde Park, New York. Dr. Schneider has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Cerebellum Agenesis Hydrocephaly. His top areas of expertise are Cerebellum Agenesis Hydrocephaly, Hydrocephalus, Dysembryoplastic Neuroepithelial Tumors (DNET), Posterior Fossa Decompression, and Endoscopic Transnasal Transsphenoidal Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schulder's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 11 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile